Alto Neuroscience (ANRO) Research & Development (2023 - 2026)
Alto Neuroscience (ANRO) posted Research & Development of $20.3 million for Q1 2026, up 69.17% sequentially from $12.0 million in Q4 2025, and up 103.47% YoY from $10.0 million in Q1 2025.
Alto Neuroscience (ANRO) Research & Development (2023 - 2026) Analysis & Trends
Alto Neuroscience has reported Research & Development for 4 years, with the latest figure at $20.3 million in Q1 2026.
- Quarterly Research & Development rose 103.47% year-over-year to $20.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $55.9 million (up 18.97% YoY) and the FY2025 annual result came in at $45.6 million, down 2.93% from the prior year.
- Research & Development grew to $20.3 million in Q1 2026 per ANRO's latest filing, from $12.0 million in the prior quarter.
- Over five years, Research & Development peaked at $20.3 million in Q1 2026 and troughed at -$20.4 million in Q4 2023.
- A 4-year average of $8.7 million and a median of $10.5 million in 2025 frame the typical range for Research & Development.
- The sharpest annual moves came in 2024 and 2025: Research & Development jumped 152.82% in 2024, then dropped 19.41% in 2025.
- Over 4 years, Research & Development stood at -$20.4 million in 2023, then surged by 152.82% to $10.8 million in 2024, then increased by 11.07% to $12.0 million in 2025, then surged by 69.17% to $20.3 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $20.3 million, $12.0 million, and $10.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Alto Neuroscience | 1.13 Bn | 1.13 Bn | - | 22.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.11 Mn |
| Mar 31, 2026 | 20.29 Mn |
| Dec 31, 2025 | 12.00 Mn |
| Sep 30, 2025 | 10.53 Mn |
| Jun 30, 2025 | 13.12 Mn |
| Mar 31, 2025 | 9.97 Mn |
| Dec 31, 2024 | 10.80 Mn |
| Sep 30, 2024 | 13.06 Mn |
| Jun 30, 2024 | 13.18 Mn |
| Mar 31, 2024 | 9.95 Mn |
| Dec 31, 2023 | -20.45 Mn |
| Sep 30, 2023 | 7.97 Mn |
| Jun 30, 2023 | 7.07 Mn |
| Mar 31, 2023 | 5.61 Mn |